Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dead B. subtilis
- Development stage
- Unknown
- Lead developer
- Jinling Hospital
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**Dead B. subtilis** (inactivated *Bacillus subtilis*) is an inactivated probiotic preparation being investigated for the treatment of irritable bowel syndrome with diarrhea (IBS-D). Developed by Jinling Hospital in China, this postbiotic therapy is being evaluated in a clinical trial (NCT06612411) to determine its efficacy in improving clinical symptoms and its impact on host-microbiota maladaptation, specifically focusing on purine metabolism and hypoxanthine biosynthesis. Unlike live probiotics, dead or inactivated *B. subtilis* offers a stable alternative that may modulate the gut microbiome and metabolic pathways without the risks associated with live bacterial colonization.
- Other names
- Dead B. subtilisdead Bacillus subtilisheat-killed B. subtilisheat-killed Bacillus subtilisinactivated B. subtilisinactivated Bacillus subtilis
Beyond the preview
Go deeper on Dead B. subtilis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dead B. subtilis.